No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Express News | China Resources Sanjiu Says It Is Set to Become Tasly's Controlling Shareholder After the Transaction, China Resources to Become Tasly's Actual Controller
Express News | China Resources Sanjiu Medical & Pharmaceutical Says It Plans to Buy 28% Stake in Tasly
These 4 Measures Indicate That China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Is Using Debt Safely
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): The overseas business accounts for a relatively small proportion of the company's overall business.
Gelonghui reported on February 11 that China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated on the investor interaction platform that overseas Business accounts for a small proportion of the company's overall Business.
China Resources 39:2024 Annual Results Report
China Resources Sanjiu Medical & Pharmaceutical's (SZSE:000999) Investors Will Be Pleased With Their Strong 123% Return Over the Last Three Years
